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INTRODUCTION {#s1}
============

Hereditary hemochromatosis (HH) is a common autosomal recessive disease leading to iron over-load and end-organ damage. The most prevalent cause of HH is a missense mutation of HFE on chromosome 6 made by substitution of tyrosine for cysteine at amino acid 282 (C282Y).^[@R01]^ Despite the high prevalence of HFE mutation among European ancestry, studies of African and Asian ethnicities have found very low prevalence of the HFE mutation.^[@R02]-[@R06]^ A genetic study performed in 224 healthy individuals in Tehran showed that only 2.2% were heterozygous for the C282Y HFE mutation and there were no homozygous cases.^[@R02]^ Hemojuvelin mutation (HJV) located on chromosome 1 has been found to cause juvenile hemochromatosis (JH) with clinical symptoms in the second decade of life. This clinical consequences of this mutation is more severe than HFE related HH.^[@R07],[@R08]^ Contrary to HFE related HH, in HJV hemochromatosis a range of different types of mutations has been reported. Papanikolaou et al. showed that 80% of HJV mutations are p.G320V, however until now more than 25 different mutations in the HJV gene have been described.^[@R07],[@R09],[@R10]^

In this report we aim to present clinical, laboratory, genetic and follow up data of a family with an HJV mutation in 3 affected members who are residents of Western Iran. This is the first report of an HJV mutation from Iran.

MATERIALS AND METHODS {#s2}
=====================

Subjects {#s2-1}
--------

We studied a family pedigree from Western Iran that originated from Kurd and Lur ethnicity (I-1, I-4: of Lur and I-2, I-3: Kurd ethnicity) and has 43 members. Study approval was obtained by the Digestive Disease Research Institute (DDRI) Ethical Committee and all 9 subjects who gave blood samples signed informed consents to participate in this study.

History and physical examination {#s2-2}
--------------------------------

A thorough history was taken and complete physical examination was performed for the proband (III-9) and his family.

Laboratory and imaging investigations {#s2-3}
-------------------------------------

A primary laboratory examination (complete blood count, iron indices, liver function test, and hepatic viral marker) was performed for all family members. In addition, serial laboratory examinations (liver elastography, abdominal MRI) were performed for the proband and his affected sister both before and after therapy.

Genetic studies {#s2-4}
---------------

For analysis of the HFE, HAMP, TfR2, and HJV coding regions (exons plus intron--exon boundaries), PCR-amplified fragments were purified with the QIAquick PCR Purification Kit (Qiagen, Valencia, CA) and sequenced by using the Dye-terminato Cycle-sequencing Kit (Beckman Coulter Inc.). Fragments were then electrophoretically separated and analyzed with a CEQ 8000 XL Beckman Coulter DNA sequencer.

RESULTS {#s3}
=======

The proband was visited in our clinic in Tehran for the first time in 2009. He was a 26-year-old man who referred to our center because of weakness, skin hyperpigmentation and occasional dyspnea from three months before admission. He also complained of decreased libido. The only positive finding in physical examination was hyperpigmentation in the forehead area. His older brother who also had skin hyperpigmentation died at age 24 years of heart disease in the year 2005. The etiology of his heart disease was not known. With a clinical suspicion of JH, an iron profile and further studies were performed ([Table 1](#T1){ref-type="table"}). Liver transaminases and alkaline phosphatase were reported to be two times normal and liver elastography revealed moderate increase in liver stiffness \[Fibroscan score=7.8 kilo pascal (KP)\]. Abdominal CT scan revealed a relatively hyperdense liver in comparison with the spleen. Likewise, there was significant decrease in hepatic signal intensity without signal alteration of the spleen in magnetic resonance imaging (MRI) which was compatible with hereditary hepatic iron overload ([Figures 1 A](#F01){ref-type="fig"}, [B](#F02){ref-type="fig"}). Echocardiography was reported to be normal with a normal ejection fraction. All other work ups for underlying liver disease were negative. A clinical diagnosis of JH was made and a family screening for iron profile and genetic study was planned. Therapeutic biweekly phlebotomy was started after the second visit.

###### Proband's laboratory data.

  ------------------------ -------------- ------------ ---------------- ----------------- ----------------- ----------------- ----------------- -----------------
                           **Visits**     **First**\   **After 6 mo**   **After 12 mo**   **After 18 mo**   **After 24 mo**   **After 30 mo**   **After 36 mo**
                                          **visit**                                                                                             

  Blood count              Hb (g/dl)      14.2         14.3             14.9              13                16.3              15.3              14.3

  Plat (mm^3^ )            135000         140000       145000           150000            183000            144000            192000            

  Iron indices             Iron (µg/dl)   265          220              240               255               313               162               95

  TIBC (µg/dl)             312            300          320              340               384               408               280               

  Tsat (%)                 85             73           75               75                81                40                34                

  Ferritin (ng/ml)         \>2000         2990         2247             917               253               193               21                

  Liver function studies   AST (U/l)      65           103              80                30                25                16                20

  ALT (U/l)                69             90           80               32                29                26                21                

  ALK phos (U/l)           570            551          456              440               389               363               250               

  Liver\                   Score (KP)     7.8                                                                                 5.8               
  Stiffness                                                                                                                                     
  ------------------------ -------------- ------------ ---------------- ----------------- ----------------- ----------------- ----------------- -----------------

Hb: Hemoglobin, Plat: Platelets, TIBC: Transferrin iron binding capacity, Tsat: Transferrin phosphatase, GGT: Gamma glutamate transferase, PT: Prothrombin time, KP: Kilo pascal

###### Fig 1

Proband's pre- (A, B) and post-(C, D) treatment liver imaging studies. Increased density of the liver visualized on the CT scan (A) compared to the spleen with considerable hypointensity of the liver in axial T1-weighted MR image (B). Normal appearing hepatic signal intensity in axial T1-weighted MR image after treatment (C), confirmed by axial T2\*-weighted MR image (D) as the most sensitive sequence for iron detection which revealed a normal mean T2\* value of 22.4 msec.
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Further investigation showed that the proband's brother (III-10) ([Figure 2](#F05){ref-type="fig"}) died of cardiac disease in year 2005 at the age of 24. Unfortunately no medical work up was made to search for hemochromatosis in this case. Other family members had no clinical symptoms or signs of hemochromatosis.
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In family member screening of iron indices in 2010, the proband's 30 year old sister (III-7) although asymptomatic, was found to have a high serum ferritin level with increased liver stiffness on elastography (liver fibrosis score: 27 KP). She began biweekly phlebotomy treatments. [Table 2](#T2){ref-type="table"} shows her laboratory data for sequential visits. With the exception of the proband's father who was determined to be seropositive for HBSAg with a normal liver function test and negative serum HBV-DNA (inactive HBV carrier state) all other family members had normal laboratory studies ([Table 3](#T3){ref-type="table"}).

###### Laboratory data for proband\'s sister.

  ---------------------------- --------------- ------------- -------------- ---------------
  **Complete blood count**     **Hb (g/dl)**   **14.5**      **13.6**       **13**
                               Plat (mm^3^ )   154000        193000         189000
  **Iron indices**             Iron (µg/dl)    235           248            151
  TIBC (µg/dl)                 320             309           300            
  Tsat (%)                     73              80            50             
  Ferritin (ng/ml)             4350            1305          192            
  **Liver function studies**   AST (U/l)       58            36             29
  ALT (U/l)                    85              31            28             
  ALK phos (U/l)               353             268           254            
  **Fibroscan**                Score (KP)      27                           6.8
                               Visits          First visit   After 1 year   After 3 years
  ---------------------------- --------------- ------------- -------------- ---------------

Hb: Hemoglobin, Plat: Platelets, TIBC: Transferrin iron binding capacity, Tsat: Transferrin saturation, AST:

Aspartate aminotransferase, ALT: Alanine aminotransferase, ALK phos: Alkaline phosphatase, GGT: Gamma glutamate transferase, KP: Kilo pascal

###### Results of proband family member's laboratory investigations

  -------------------------- ------------ -------------- ------------- ------------- ------------- ------------- ------------- --------- --------------- -----------
                             **Hb**\      **PLT**\       **ALT**\      **AST**\      **ALP**\      **Fe**\       **TIBC**\     **TS**\   **Ferritin**\   **HBsAg**
                             **(g/dl)**   **(mm^3^ )**   **(U/lit)**   **(U/lit)**   **(U/lit)**   **(µg/dl)**   **(µg/dl)**   **(%)**   **(ng/dl)**     

  **Father (61 y)**          14.9         211000         19            24            190           91            303           30        112.7           Pos

  **Mother (58 y)**          14.4         254000         14            15            289           68            369           18        188.4           Neg

  **Sibling 1 (34 y)**       12.7         282000         13            18            195           75            394           19        26.76           Neg

  **Sibling 2 (31 y)**       15.2         224000         \-            \-            \-            79            347           22        128.8           Neg

  **Sibling 3 (24 y)**       13.9         224000         22            22            263           97            391           25        82.91           Neg

  **Sibling 4 (21 y)**       13.8         202000         10            14            230           56            420           13        10.22           Neg

  **Grandson (15 y)**        14.6         197000         13            15            220           50            400           12.5      20              Neg

  **Granddaughter (10 y)**   12.2         289000         16            20            200           60            370           16        20              Neg
  -------------------------- ------------ -------------- ------------- ------------- ------------- ------------- ------------- --------- --------------- -----------

Hb: Hemoglobin, TIBC: Transferrin iron binding capacity, Tsat: Transferrin saturation, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase, HBsAg: Hepatitis B surface antigen, y: Year-old, Pos: Positive, Neg: Negative

Genetic studies of the third generation and their parents showed that the proband, case III-9 was a homozygote c.265T\>C (p.C89R) HJV mutation + a heterozygote c.884T\>C (p.V295A) mutation for HFE. The latter mutation has been described previously.^[@R11],[@R12]^ The proband's sister, case III-7, had evidence of the same homozygote HJV mutation found in the proband, namely c.265T\>C (p.C89R). Also HJV c.98-6C\>G (rs56025621) polymorphic variant was found in cis in the sister (homozygote) and the proband (homozygote). Cases III-1 and III- 5 were also heterozygous for the HFE c.884T\>C (p.V295A) mutation. Both parents (II-10 and II-11) were heterozygous for the HJV c.265T\>C (p.C89R) mutation and the mother was also heterozygous for the HFE c.884T\>C (p.V295A) mutation ([Figure 2](#F05){ref-type="fig"}).

Our case of JH presented with deceased libido, skin hyperpigmentation, and dyspnea. His symptoms all subsided following 3 years of phlebotomy. Currently he is alive and healthy. His post-treatment MRI image was almost normal. The pretreat ment MRI showed a very hypointense liver image, however on the post-treatment MRI the intensity of the liver became equal to that of the spleen. ([Figures 2 C,D](#F05){ref-type="fig"}). The proband's brother died of hemochromatosis early in life and his asymptomatic sister was homozygous for HJV with increased stiffness of liver as measured by liver elastography, which was suggestive of an underlying iron-induced liver disease.

DISCUSSION {#s4}
==========

JH occurs equally in both sexes. Patients usually present with hypogonadism and cardiac symptoms as early as the second decade of life. Delay in diagnosis and treatment of JH patients may lead to death from cardiac involvement as was likely the case in the proband's brother.^[@R08]^ The etiology of JH is a genetic mutation in either the HJV or HAMP genes. It has been reported that about 80% of JH patients from central Europe have at least one copy of the G320V mutation.7 However, until now, studies showed numerous other mutations in the HJV gene.^[@R09],[@R10],[@R13]^

The proband was homozygous for HJV and heterozygous for HFE in comparison to his sister who was only homozygous for HJV ([Figure 2](#F05){ref-type="fig"}). HFE heterozygosity might be a possible reason for the symptoms seen in the proband. Some studies have shown that HFE homozygotes with heterozygote mutations of the HJV or HAMP genes exhibited increased severity of symptoms,^[@R14],[@R15]^ although others disagree.^[@R16],[@R17]^ However, considering that subjects with heterozygote mutation of the HFE gene have lower degrees of iron-overload (if any) and no clinical symptoms,^[@R18]^ it seems unlikely that the reported HFE heterozygosis might have had a modifier effect on the proband's clinical symptoms. Of note, when the proband's brother died, the physician who treated his brother did not consider HH and told the father that his son died because of weakness and that the other sons should consume more meat. Therefore, the proband was placed on a high protein diet by the father and was forced to eat kebab even in the morning. His affected sister who was married and had two children, had regular menstruation. For this reason she was symptomless despite the presence of iron overload.

The HJV c.265T\>C (p.C89R) mutation is a novel mutation and there is no information about its functional effect on the hemojuvelin protein. However, all of the five mutation function predicting algorithms (SIFT, PolyPhen2, Mutation Taster, Mutation Assessor, and FATHMM) of the dbNSFP database^[@R19]^ predicted this mutation to be pathogenic.

HH is reported to be very rare in Iran and the reported rate of HFE mutation is very low in the normal Iranian population.^[@R02],[@R05]^ Of the few cases of HH that have been reported in Iran, all were non-HFE mutations. However these cases did not undergo additional genetic analyses to search for mutations in other HH genes.^[@R04],[@R06]^ To the best of our knowledge this is the first report of an HJV mutation from Iran which is reported as a novel HJV mutation (p.C89R).

We were able to diagnose both patients with HH without performing a liver biopsy and the iron measurement in the biopsy samples as classically recommended. Recently, elastography has been shown to be an effective method for diagnosis of liver fibrosis and portal hypertension.^[@R20],[@R21]^ One study has shown the effectiveness of elastography in measurement of liver fibrosis in patients with hemochromatosis.^[@R22]^ Therefore using noninvasive measures such as MRI imaging and elastography along with the availability of genetic information seems to be more convenient and safe. This may replace liver biopsy and iron measurements in biopsy specimens.

It is very important to know that HH due to a mutation in HJV and probably other genes when sought for can be found and prevent liver mortality from HH. Therefore clinicians in Iran and other regional countries should be more vigilant, consider HH when a compatible clinical presentation is evident, and have a higher index of suspicion for this treatable disease.
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